GlassScriptPhysician profile
Ratna S Danda
NPI 1467481382
$8,553.59
in general payments reported to CMS, 2019-2025
40 companies · $1,479 in 2025
The $1,479 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,439 · 2020: $453 · 2021: $728 · 2022: $1,570 · 2023: $1,503 · 2024: $1,382 · 2025: $1,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,364 · Education: $0.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,363.71 |
| Education | $0.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,334.45 | 2019-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $752.76 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $704.31 | 2021-2025 | |
| Amgen INC. | $688.87 | 2019-2025 | Krystexxa, Tavneos |
| Opko Pharmaceuticals, LLC | $494.37 | 2019-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $481.96 | 2022-2024 | Benlysta, Jesduvroq |
| Otsuka America Pharmaceutical, INC. | $466.11 | 2019-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $463.62 | 2019-2024 | Veltassa |
| Akebia Therapeutics INC | $452.87 | 2019-2025 | Vafseo, Auryxia |
| Aurinia Pharma U.S., INC. | $356.49 | 2021-2024 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $336.44 | 2019-2025 | Ultomiris |
| Calliditas Therapeutics US INC. | $326.74 | 2023-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $310.24 | 2019-2024 | Velphoro |
| Travere Therapeutics, INC. | $165.35 | 2022-2025 | Filspari |
| Baxter Healthcare | $136.73 | 2021-2022 |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ratna Danda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.